Brief: Shenzhen Hepalink Pharmaceutical Group Posts FY Non-IFRS Profit Attributable RMB592 Million
29/03/2021 13:36
March 29 (Reuters) - Shenzhen Hepalink Pharmaceutical Group
Co Ltd 002399.SZ :
* SHENZHEN HEPALINK PHARMACEUTICAL GROUP - PROPOSED FINAL
DIVIDEND
OF RMB0.15 PER SHARE
* FY NON-IFRS PROFIT ATTRIBUTABLE TO EQUITY HOLDERS RMB592
MILLION
VERSUS RMB446.3 MILLION
* FY REVENUE RMB5.32 BLN VS RMB4.61 BLN
Source text for Eikon: urn:newsml:reuters.com:*:nHKSfGSyx
Further company coverage: 002399.SZ
(Reuters.Briefs@thomsonreuters.com)
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA